2004
Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer
Sandler A, Blumenschein G, Henderson T, Lee J, Truong M, Kim E, Mass B, Garcia B, Johnson D, Herbst R. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. Journal Of Clinical Oncology 2004, 22: 2000-2000. DOI: 10.1200/jco.2004.22.14_suppl.2000.Peer-Reviewed Original ResearchPhase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer
Sandler A, Blumenschein G, Henderson T, Lee J, Truong M, Kim E, Mass B, Garcia B, Johnson D, Herbst R. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. Journal Of Clinical Oncology 2004, 22: 2000-2000. DOI: 10.1200/jco.2004.22.90140.2000.Peer-Reviewed Original Research
2003
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Herbst RS, Bunn PA. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clinical Cancer Research 2003, 9: 5813-24. PMID: 14676101.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLung cancerEGFR-TK inhibitorsSystemic chemotherapyClinical trialsClinical developmentMetastatic non-small cell lung cancerTwo-drug combination regimenEpidermal growth factor receptor tyrosine kinase inhibitor gefitinibSingle-agent activityRate of deathNew treatment approachesKinase inhibitor gefitinibEpidermal growth factor receptorGrowth factor receptorCombination regimenDisease progressionPlatinum agentsTreatment approachesSolid tumorsTumor growthInhibitor gefitinibTherapyCancerO-112 A phase I/II study of the anti-VEGF MAb bevacizumab (Avastin™) and erlotinib (Tarceva™), a HER1/EGFR-TK inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung cancer
Sandler A, Mininberg E, Henderson T, Kim E, Hong W, Mass R, Novotny W, Garcia B, Herbst R, Johnson D. O-112 A phase I/II study of the anti-VEGF MAb bevacizumab (Avastin™) and erlotinib (Tarceva™), a HER1/EGFR-TK inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung cancer. Lung Cancer 2003, 41: s36. DOI: 10.1016/s0169-5002(03)91770-3.Peer-Reviewed Original Research